Loading…
Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani
Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution+sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. ro...
Saved in:
| Published in: | Vaccine 2001-04, Vol.19 (23-24), p.3104-3115 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c421t-90b2b4cf3db5cc41ec2e70b19ef9fbc75dea21797cfe9883535c0f2f1a157bc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c421t-90b2b4cf3db5cc41ec2e70b19ef9fbc75dea21797cfe9883535c0f2f1a157bc3 |
| container_end_page | 3115 |
| container_issue | 23-24 |
| container_start_page | 3104 |
| container_title | Vaccine |
| container_volume | 19 |
| creator | Paraguai de Souza, Edilma Bernardo, Robson Roney Palatnik, Marcos Palatnik de Sousa, Clarisa Beatriz |
| description | Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution+sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. route, inducing a strong and specific protective effect against experimental visceral leishmaniasis shown by the increase of: specific IgG antibodies (82.6%), mainly IgG2a, the delayed type of hypersensitivity to promastigote lysate (37.8%, P |
| doi_str_mv | 10.1016/S0264-410X(01)00031-7 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77066004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X01000317</els_id><sourcerecordid>77066004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-90b2b4cf3db5cc41ec2e70b19ef9fbc75dea21797cfe9883535c0f2f1a157bc3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EokvhI4B8QAgOoR47iZMTggoK0kogUSFuljMZ7xolzhJ7F3rjo-P9o8KtJ4-l33sev8fYUxCvQUB98VXIuixKEN9fCnglhFBQ6HtsAY1Whayguc8Wt8gZexTjjwxVCtqH7AxAgcy3BfvzzSL6YJOfAp8cf2eH7gL56JG4XVkfYuL0e0OzHykkO_Cdj0hzHgbycT3a4G30kf_yac3TmvjVF1Xz1XCD02aeEvnAbUh-RQf35a2G91OYdnl6zB44O0R6cjrP2fWH99eXH4vl56tPl2-XBZYSUtGKTnYlOtV3FWIJhJK06KAl17oOddWTlaBbjY7aplGVqlA46cBCpTtU5-zF0TZv9XNLMZlx_5FhsIGmbTRai7oWorwTBN3oBiRksDqCOE8xzuTMJodk5xsDwuwrMoeKzD5_I8AcKjI6656dHth2I_X_VKdOMvD8BNiIdnCzDejjf-6VbKTI2JsjRjm1nafZRPQUkHo_EybTT_6OTf4C0_qv0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17878121</pqid></control><display><type>article</type><title>Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani</title><source>ScienceDirect Freedom Collection</source><creator>Paraguai de Souza, Edilma ; Bernardo, Robson Roney ; Palatnik, Marcos ; Palatnik de Sousa, Clarisa Beatriz</creator><creatorcontrib>Paraguai de Souza, Edilma ; Bernardo, Robson Roney ; Palatnik, Marcos ; Palatnik de Sousa, Clarisa Beatriz</creatorcontrib><description>Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution+sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. route, inducing a strong and specific protective effect against experimental visceral leishmaniasis shown by the increase of: specific IgG antibodies (82.6%), mainly IgG2a, the delayed type of hypersensitivity to promastigote lysate (37.8%, P<0.001), the in vitro cellular proliferative response to GP36 of ganglia lymphocytes (53.5%, P<0.005) and the decrease of liver parasite burden (68.1%, P<0.025). Saponin treated controls reacted significantly differently from GP36 vaccinated animals at all the assayed variables (P<0.05). GP36 induced significant protection against murine visceral leishmaniasis at concentrations commonly used for vaccination with recombinant antigens.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(01)00031-7</identifier><identifier>PMID: 11312005</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject><![CDATA[Adjuvants ; Animals ; Antibodies, Protozoan - biosynthesis ; Antigens, Protozoan - administration & dosage ; Antigens, Protozoan - isolation & purification ; Biological and medical sciences ; Female ; Fundamental and applied biological sciences. Psychology ; glycoprotein gp36 ; GP36 glycoprotein ; Immunity, Cellular ; Leishmania donovani ; Leishmania donovani - immunology ; Leishmaniasis, Visceral - immunology ; Leishmaniasis, Visceral - prevention & control ; Mice ; Mice, Inbred BALB C ; Murine visceral leishmaniasis ; Native antigen ; Protozoa ; Protozoan Proteins - administration & dosage ; Protozoan Proteins - immunology ; Protozoan Proteins - isolation & purification ; Protozoan Vaccines - administration & dosage ; Saponin ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies]]></subject><ispartof>Vaccine, 2001-04, Vol.19 (23-24), p.3104-3115</ispartof><rights>2001 Elsevier Science Ltd</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-90b2b4cf3db5cc41ec2e70b19ef9fbc75dea21797cfe9883535c0f2f1a157bc3</citedby><cites>FETCH-LOGICAL-c421t-90b2b4cf3db5cc41ec2e70b19ef9fbc75dea21797cfe9883535c0f2f1a157bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1052820$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11312005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paraguai de Souza, Edilma</creatorcontrib><creatorcontrib>Bernardo, Robson Roney</creatorcontrib><creatorcontrib>Palatnik, Marcos</creatorcontrib><creatorcontrib>Palatnik de Sousa, Clarisa Beatriz</creatorcontrib><title>Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution+sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. route, inducing a strong and specific protective effect against experimental visceral leishmaniasis shown by the increase of: specific IgG antibodies (82.6%), mainly IgG2a, the delayed type of hypersensitivity to promastigote lysate (37.8%, P<0.001), the in vitro cellular proliferative response to GP36 of ganglia lymphocytes (53.5%, P<0.005) and the decrease of liver parasite burden (68.1%, P<0.025). Saponin treated controls reacted significantly differently from GP36 vaccinated animals at all the assayed variables (P<0.05). GP36 induced significant protection against murine visceral leishmaniasis at concentrations commonly used for vaccination with recombinant antigens.</description><subject>Adjuvants</subject><subject>Animals</subject><subject>Antibodies, Protozoan - biosynthesis</subject><subject>Antigens, Protozoan - administration & dosage</subject><subject>Antigens, Protozoan - isolation & purification</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>glycoprotein gp36</subject><subject>GP36 glycoprotein</subject><subject>Immunity, Cellular</subject><subject>Leishmania donovani</subject><subject>Leishmania donovani - immunology</subject><subject>Leishmaniasis, Visceral - immunology</subject><subject>Leishmaniasis, Visceral - prevention & control</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Murine visceral leishmaniasis</subject><subject>Native antigen</subject><subject>Protozoa</subject><subject>Protozoan Proteins - administration & dosage</subject><subject>Protozoan Proteins - immunology</subject><subject>Protozoan Proteins - isolation & purification</subject><subject>Protozoan Vaccines - administration & dosage</subject><subject>Saponin</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqFkU9v1DAQxS0EokvhI4B8QAgOoR47iZMTggoK0kogUSFuljMZ7xolzhJ7F3rjo-P9o8KtJ4-l33sev8fYUxCvQUB98VXIuixKEN9fCnglhFBQ6HtsAY1Whayguc8Wt8gZexTjjwxVCtqH7AxAgcy3BfvzzSL6YJOfAp8cf2eH7gL56JG4XVkfYuL0e0OzHykkO_Cdj0hzHgbycT3a4G30kf_yac3TmvjVF1Xz1XCD02aeEvnAbUh-RQf35a2G91OYdnl6zB44O0R6cjrP2fWH99eXH4vl56tPl2-XBZYSUtGKTnYlOtV3FWIJhJK06KAl17oOddWTlaBbjY7aplGVqlA46cBCpTtU5-zF0TZv9XNLMZlx_5FhsIGmbTRai7oWorwTBN3oBiRksDqCOE8xzuTMJodk5xsDwuwrMoeKzD5_I8AcKjI6656dHth2I_X_VKdOMvD8BNiIdnCzDejjf-6VbKTI2JsjRjm1nafZRPQUkHo_EybTT_6OTf4C0_qv0w</recordid><startdate>20010430</startdate><enddate>20010430</enddate><creator>Paraguai de Souza, Edilma</creator><creator>Bernardo, Robson Roney</creator><creator>Palatnik, Marcos</creator><creator>Palatnik de Sousa, Clarisa Beatriz</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>20010430</creationdate><title>Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani</title><author>Paraguai de Souza, Edilma ; Bernardo, Robson Roney ; Palatnik, Marcos ; Palatnik de Sousa, Clarisa Beatriz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-90b2b4cf3db5cc41ec2e70b19ef9fbc75dea21797cfe9883535c0f2f1a157bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adjuvants</topic><topic>Animals</topic><topic>Antibodies, Protozoan - biosynthesis</topic><topic>Antigens, Protozoan - administration & dosage</topic><topic>Antigens, Protozoan - isolation & purification</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>glycoprotein gp36</topic><topic>GP36 glycoprotein</topic><topic>Immunity, Cellular</topic><topic>Leishmania donovani</topic><topic>Leishmania donovani - immunology</topic><topic>Leishmaniasis, Visceral - immunology</topic><topic>Leishmaniasis, Visceral - prevention & control</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Murine visceral leishmaniasis</topic><topic>Native antigen</topic><topic>Protozoa</topic><topic>Protozoan Proteins - administration & dosage</topic><topic>Protozoan Proteins - immunology</topic><topic>Protozoan Proteins - isolation & purification</topic><topic>Protozoan Vaccines - administration & dosage</topic><topic>Saponin</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paraguai de Souza, Edilma</creatorcontrib><creatorcontrib>Bernardo, Robson Roney</creatorcontrib><creatorcontrib>Palatnik, Marcos</creatorcontrib><creatorcontrib>Palatnik de Sousa, Clarisa Beatriz</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paraguai de Souza, Edilma</au><au>Bernardo, Robson Roney</au><au>Palatnik, Marcos</au><au>Palatnik de Sousa, Clarisa Beatriz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2001-04-30</date><risdate>2001</risdate><volume>19</volume><issue>23-24</issue><spage>3104</spage><epage>3115</epage><pages>3104-3115</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution+sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. route, inducing a strong and specific protective effect against experimental visceral leishmaniasis shown by the increase of: specific IgG antibodies (82.6%), mainly IgG2a, the delayed type of hypersensitivity to promastigote lysate (37.8%, P<0.001), the in vitro cellular proliferative response to GP36 of ganglia lymphocytes (53.5%, P<0.005) and the decrease of liver parasite burden (68.1%, P<0.025). Saponin treated controls reacted significantly differently from GP36 vaccinated animals at all the assayed variables (P<0.05). GP36 induced significant protection against murine visceral leishmaniasis at concentrations commonly used for vaccination with recombinant antigens.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>11312005</pmid><doi>10.1016/S0264-410X(01)00031-7</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2001-04, Vol.19 (23-24), p.3104-3115 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77066004 |
| source | ScienceDirect Freedom Collection |
| subjects | Adjuvants Animals Antibodies, Protozoan - biosynthesis Antigens, Protozoan - administration & dosage Antigens, Protozoan - isolation & purification Biological and medical sciences Female Fundamental and applied biological sciences. Psychology glycoprotein gp36 GP36 glycoprotein Immunity, Cellular Leishmania donovani Leishmania donovani - immunology Leishmaniasis, Visceral - immunology Leishmaniasis, Visceral - prevention & control Mice Mice, Inbred BALB C Murine visceral leishmaniasis Native antigen Protozoa Protozoan Proteins - administration & dosage Protozoan Proteins - immunology Protozoan Proteins - isolation & purification Protozoan Vaccines - administration & dosage Saponin Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies |
| title | Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A39%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20of%20Balb/c%20mice%20against%20experimental%20visceral%20leishmaniasis%20with%20the%20GP36%20glycoprotein%20antigen%20of%20Leishmania%20donovani&rft.jtitle=Vaccine&rft.au=Paraguai%20de%20Souza,%20Edilma&rft.date=2001-04-30&rft.volume=19&rft.issue=23-24&rft.spage=3104&rft.epage=3115&rft.pages=3104-3115&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(01)00031-7&rft_dat=%3Cproquest_cross%3E77066004%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-90b2b4cf3db5cc41ec2e70b19ef9fbc75dea21797cfe9883535c0f2f1a157bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17878121&rft_id=info:pmid/11312005&rfr_iscdi=true |